BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Atavistik Bio\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Atavistik Bio\, Inc.'s drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07601425-9127@assetmemo.bio
DTSTAMP:20261121T005943Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:ATV-1601: Phase 1/2 readout est. (NCT07601425)
DESCRIPTION:ATV-1601\, phase 1/2.\nStudy: Harmony-HHT: ATV-1601 in Particip
 ants With Hereditary Hemorrhagic Telangiectasia (HHT)\nEstimated primary c
 ompletion: December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/atv-1601#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07601425
URL:https://assetmemo.bio/drug/atv-1601#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
